syros pharmaceuticals的罕見血液癌症治療方案新數據顯示不能成功，盤前股

快訊 · 08/13 19:59

Syros Pharmaceuticals Shares Down 62.5% at $1.88 Premarket After Interim Data Shows Co's Rare Blood Cancer Therapy Unlikely to Suceed in Study

syros pharmaceuticals的罕見血液癌症治療方案新數據顯示不能成功，盤前股價暴跌62.5%，跌至1.88美元。